While B2M and CD298 are useful for human samples, there are no validated markers that are robustly expressed by commonly used mouse cancer cell lines (e.g., MC38, CT26, B16, KPC, and Panc02), which are critical components of many syngeneic immunocompetent studies. This evidence concerns the gene B2M and cancer.